Selected data models

You must log in to select data models for download or further analysis.

2 Search results.
Relevance Rating New first Old first

Eligibility Renal Cell Carcinoma and B-Cell Non-Hodgkin's Lymphoma NCT00944905

- 8/27/18 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00944905

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - Patient Enrollment

- 7/10/18 - 1 form, 11 itemgroups, 39 items, 1 language
Itemgroups: Demographics, Lymphoid Neoplasms; Inclusion Criteria, CD20 antigen; Inclusion Criteria, Prior chemotherapy; Inclusion Criteria, Karnofsky Performance Status; Survival time, Anticipated; Inclusion Criteria, ANC; Platelet Count; Inclusion Criteria, Renal function; Hepatic function; Inclusion Criteria, Bi-dimensionally measured disease; Inclusion Criteria, Age; Inclusion Criteria, Informed Consent; Inclusion Criteria, Exclusion criteria
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial